Highmark Commercial Medical Policy - Pennsylvania |
Medical Policy: | R-68-002 |
Topic: | Radiation Therapy for Head and Neck Cancer |
Section: | Radiation Therapy & Nuclear Medicine |
Effective Date: | August 1, 2018 |
Issue Date: | July 30, 2018 |
Last Reviewed: | May 2018 |
Radiation therapy is considered an integral component in the multidisciplinary management of malignancies of the head and neck region. Primary anatomic sites included in this category include paranasal sinuses (ethmoid and maxillary), salivary glands, the lip, oral cavity, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, nasopharynx, and occult/unknown head and neck primary sites. |
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Policy Position Coverage is subject to the specific terms of the member’s benefit plan. |
Radiation therapy techniques
Radiation therapy treatment intent/timing
Radiation therapy, brachytherapy
Radiation therapy, palliative
Re-treatment for salvage after prior radiation
Refer to medical policy R-64, Neutron Beam Therapy, for additional information. |
Professional Statements and Societal Positions |
Per the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Head and Neck Cancers, “In general, the reirradiated population of head and neck cancer patients as described in the current literature represents a diverse but highly selected group of patients treated in centers where there is a high level of expertise and systems in place for managing acute and long-term toxicities. When the goal of treatment is curative and surgery is not an option, reirradiation strategies can be considered for patients who: develop locoregional failures or second primaries at greater than or equal to six(6) months after the initial radiotherapy; can receive additional doses of radiotherapy of at least 60 Gy; and can tolerate concurrent chemotherapy. Organs at risk for toxicity should be carefully and analyzed through review of dose volume histograms, and consideration for acceptable doses should be made on the basis of time interval since original radiotherapy, anticipated volumes to be included, and patient’s life expectancy.” |
Place of Service: Outpatient |
Radiation therapy for head and neck cancer is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.
The policy position applies to all commercial lines of business |
Denial Statements |
Services that do not meet the criteria of this policy will not be considered medically necessary. A network provider cannot bill the member for the denied service unless: (a) the provider has given advance written notice, informing the member that the service may be deemed not medically necessary; (b) the member is provided with an estimate of the cost; and (c) the member agrees in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Links |
05/2018, REMINDER: Radiation Therapy
01/2018, REMINDER: Radiation Therapy